Health Care/Hospital

Hope Rising in Hainan: International NUT Carcinoma Center Launches in Boao

BOAO, China, Jan. 29, 2026 /PRNewswire/ -- The International NUT Carcinoma Diagnosis and Treatment Center has been inaugurated at Boao International Hospital. Established through a collaboration between Boao International Hospital and Chongqing University Three Gorges Hospital, this center tackle...

2026-01-29 20:00 5609

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

-  Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study -  The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial couple...

2026-01-29 19:00 10100

Singapore hosts its first Global Health Film Festival, spotlighting pandemic and planetary health

The two-evening programme on 27-28 January at The Ngee Ann Kongsi Auditorium at the SingHealth Duke-NUS campus convened clinicians, students, policymakers and partners to focus on the importance of outbreak preparedness andplanetary health SINGAPORE, Jan. 29, 2026 /PRNewswire/ -- Singapore has ho...

2026-01-29 14:42 7613

Bupa and Tencent Launch Hong Kong's First Palm-based Check-in Service for Enhanced Healthcare Experiences

AI-powered palm verification set to deliver seamless, contactless and hygienic check-in journeys for patients at Bupa's healthcare centres HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Tencent in collaboration with Bupa Hong Kong ("Bupa"), today officially launched Hong Kong's first palm verification...

2026-01-29 10:23 6824

SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family

* Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family * Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology * SK bioscience will continue to strengthen a Mid- to Long-Term global vaccine...

2026-01-29 10:10 6976

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of68Ga-PSMA-11) for prostate cancer imaging i...

2026-01-29 07:43 7816

REPROCELL Launches StemEdit - Clinical Gene Editing Services and New iPSC Lines Using AI-Designed editing tools

BELTSVILLE, Md., Jan. 29, 2026 /PRNewswire/ -- REPROCELL today announced the commercial launch ofStemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveragingOpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEd...

2026-01-28 22:00 5376

NYSE Content Advisory: Pre-Market Update + First Lady Melania Trump to Ring NYSE Bell for Doc 'Melania'

NEW YORK, Jan. 28, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.    NYSE Content Advisory: Pre-Market Update + First Lady Melania Tr...

2026-01-28 21:55 7687

Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications

HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2 diabetes (T2DM), have been published in Nature Communications. Con...

2026-01-28 19:39 6477

CHCC 2026 Opens Registration, Offering a One-Stop Platform for Hospital Construction Solutions and Real-World Applications

TIANJIN, China, Jan. 28, 2026 /PRNewswire/ -- The 27th China Hospital Construction Conference & International Hospital Build and Infrastructure Exposition (CHCC 2026), a globally recognized hospital construction event, will be held from May 23 to 25, 2026, at the National Convention and Exhibitio...

2026-01-28 15:01 5605

US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy

The US Food and Drug Administration (FDA) has approved Novo Nordisk's new once-daily pill for weight management, designed to help people reduce excess body weight and maintain weight reduction over the long term. In clinical trials, patients achieved an average weight reduction of 16.6% from base...

2026-01-28 10:45 7778

Organizations Without AI Security Policies Are Already Behind, Warns Armor

Armor releases AI governance framework to address critical policy gap as enterprise AI adoption accelerates DALLAS, Jan. 28, 2026 /PRNewswire/ -- Armor, a leading provider of cloud-nativemanaged detection and response (MDR)

2026-01-28 02:21 5040

Home Control Signs Memorandum of Understanding with NTU Singapore to Explore AIoT Home Healthcare Ecosystem

HONG KONG, Jan. 27, 2026 /PRNewswire/ -- Home Control International Limited (" Home Control" or the "Company", together with its subsidiaries, the "Group"; Stock Code: 1747.HK) is pleased to announce that it has entered into a Strategic Memorandum of Understanding (MoU) with Nanyang Technological ...

2026-01-27 21:25 7603

Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease

Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural history expected worsening of cUHDRS in symptomatic patients of -0.73 points over nine months, based on propensity score weighting. Skyhawk also ann...

2026-01-27 21:00 8564

Libevitug Approved in China as First-in-Class Hepatitis D Treatment

BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. Libevitug is a hum...

2026-01-27 16:15 6412

Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

* Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. * Growth over the financial year was driven by increased sales in oncology, particularly in the United States. * Several partnership agreements in oncology and neurology strengthen the Group's R&D portfoli...

2026-01-27 16:00 4875

3Shape appoints Rasmus Hannemann as Senior Vice President, Portfolio & Product Strategy

COPENHAGEN, Denmark, Jan. 27, 2026 /PRNewswire/ -- 3Shape today announced the appointment of Rasmus Hannemann as Senior Vice President, Portfolio & Product Strategy, effective 9 March. Rasmus will step into the Senior Leadership Team and will report directly to CEO Jacob Paulsen. Rasmus joins 3S...

2026-01-27 15:45 6787

Getinge Q4 and Full-Year Report 2025: Organic growth and solid cash flow to end the year

GOTHENBURG, Sweden, Jan. 27, 2026 /PRNewswire/ -- "We succeeded in growing organically, delivering a record-breaking fourth quarter and organic growth at the upper end of our forecast, 4.9% for the full year," says Mattias Perjos, President & CEO at Getinge. Higher demand for consumables for ECL...

2026-01-27 15:23 4187

Davos Spotlight | EVYD, Ministry of Health Brunei Darussalam and Novartis Foundation Launch National AI-Powered Cardiovascular Disease Prevention Initiative

DAVOS, Switzerland, Jan. 27, 2026 /PRNewswire/ -- At the 2026 World Economic Forum Annual Meeting in Davos, Dr. Giovanni Caforio, Chairman of the Board of Directors of Novartis, announced a major new partnership: the Novartis Foundation, the Ministry of Health of Brunei Darussalam, and EVYD Techn...

2026-01-27 14:37 11153

Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the maintenance treatment of chronic obstructive pulmonary disease

SHANGHAI, Jan. 27, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance") today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre® (ensifentrine) for the maintenance treatment of chronic obstructive p...

2026-01-27 10:13 6651
1 ... 33343536373839 ... 541